ADC 2024 Q3 Insight Pack
Topics of interest include:
- Emerging ADC targets attracting industry investment, including TROP-2, Nectin-4, HER-3, and B7-H3
- The shift toward site-specific conjugation technologies and the innovations shaping the next generation of ADCs
All analysis was inspired by our observations of market dynamics and breaking news; alongside data from the Beacon ADC Database.
You May Also Be Interested In…
Learn More About Consulting
- We are specialist life sciences market research and consultants, delivering tailored insights across the full drug development and commercialisation lifecycle.
- Combines scientific expertise, expert networks, and proprietary Beacon data to transform complex data into clear, strategic decisions.
- Provides fully customised research, spanning qualitative interviews, quantitative analysis, and desk research, aligned to your specific business objectives.
- Helps biopharma teams reduce risk, identify opportunities, and accelerate decision-making with actionable, decision-ready insights.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
